Two of the key actionable oncogenic drivers in non-small-cell lung cancers are (1) EGFR mutations, which are the most frequently detected, being identified in 10% and 50% of cases in Western and Asian countries, respectively [2], and (2) ALK rearrangement, which occurs in approximately 5% of patients [3] (Supplementary Figure S1). This evidence concerns the gene ALK and non-small cell lung carcinoma.